Newsroom

Sorted by: Latest
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - July 24.07.2026 FJUL.LN IE000YJBT6I5  100,002.00 USD   2,856,800.64   28.567  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - April 24.07.2026 FAPR.LN IE000WX2HZQ7 250,002.00 USD 6,394,749.09 25.579  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 24.07.2026 FTFX IE00BD5HBQ97   63,402.00 USD   1,757,703.40   27.723  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - March 24.07.2026 MMAR.LN IE0002PPCMH6   50,002.00 USD   1,333,170.98   26.662  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Nuclear Power UCITS ETF 24.07.2026 RCTR.LN IE000J5PESP7 1,700,002.00 USD  30,068,203.37   17.687  ...
-

Enhanced Applauds FDA Advisory Committee's Landmark Vote to Expand Legal Compounding Pathway for Peptides

NEW YORK--(BUSINESS WIRE)--Enhanced Group Inc. (NYSE: ENHA) the elite sports competition and personalized performance products company commended the United States Food & Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee (PCAC) for its vote last week recommending that BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax be added to the FDA's Section 503A Bulk Drug Substances List. This recommendation is a critical step toward providing licensed U.S. compounding pharmacies a leg...
-

OPAL Fuels Announces Second Quarter 2026 Earnings Release Date and Conference Call

WHITE PLAINS, N.Y.--(BUSINESS WIRE)--OPAL Fuels (Nasdaq: OPAL) a leader in the production, marketing, and distribution of renewable and compressed natural gas (RNG and CNG) used as a transportation fuel for heavy duty trucking, today announced that it will release its earnings results for the second quarter ended June 30, 2026, before market open on Monday, August 10, 2026. A conference call will take place on Monday, August 10, 2026 at 11:00 a.m. Eastern Time.A listen-only connection to the inv...
-

PROCEPT BioRobotics Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – PRCT         

LOS ANGELES--(BUSINESS WIRE)--PROCEPT BioRobotics Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – PRCT...
-

EVelution Energy Confirms Substantial Groundwater Resources for First Commercial-scale Cobalt Processing Facility in the U.S.

YUMA, Ariz.--(BUSINESS WIRE)--EVelution Energy confirms substantial groundwater resources, further de-risking its planned solar-powered cobalt processing facility in Arizona....
-

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated low density lipoprotein-cholesterol (LDL-C) and early onset cardiovascular disease. Arrowhe...